The US Supreme Court has called for the Solicitor General's views in litigation between Amgen Inc. and Sandoz Inc. over the biosimilar launch notification and patent dance provisions of the biosimilars statute1. The request indicates the court is interested in the issue and may take it up.
Sandoz, a unit of Novartis AG, filed a petition with the Supreme Court in February, arguing that the Biologics Price...




